{"schema_version":"1.0","type":"article","title":"已有瘦瘦針，諾和諾德為何還要布局另一條減重路？","url":"https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs.md","lang":"zh-Hant","date":"2026-09-30","publish_at":"2026-09-30T08:00:00+08:00","updated_at":"2026-09-30","category":"製藥巨頭系列","topic":"製藥巨頭系列","tags":["Novo Nordisk","Kallyope","肥胖症","GLP-1","非腸泌素","K-554"],"summary":"諾和諾德已有GLP-1減重產品，為何仍布局非腸泌素計畫？從K-554的神經迴路假說、人體證據進度與可用劑量，分析效果、耐受性及持續使用如何影響產品價值。","key_points":[],"facts":[],"sections":["參考來源"],"references":[{"title":"[1] [Jacob Petersen原公開貼文]","source":"","date":"","url":"https://www.linkedin.com/posts/jacob-petersen-820529_im-excited-to-share-that-novo-nordisk-has-activity-7506720635704963073-rE3z/"},{"title":"[2] [Kallyope 2026策略更新（2026-01-07）]","source":"","date":"","url":"https://kallyope.com/kallyope-announces-2026-strategic-priorities-for-migraine-and-metabolism-portfolio-based-on-novel-neural-circuits-platform/"},{"title":"[3] [Novo／Kallyope研究合作公告（2018-06-19）]","source":"","date":"","url":"https://www.globenewswire.com/news-release/2018/06/19/1600406/0/en/kallyope-and-novo-nordisk-announce-collaboration-to-discover-novel-therapeutics-for-obesity-and-diabetes.html"},{"title":"[4] [Kallyope授權公告，Business Wire轉載（2024-09-10）]","source":"","date":"","url":"https://markets.financialcontent.com/wral/article/bizwire-2024-9-10-kallyope-announces-license-agreement-with-novo-nordisk"},{"title":"[5] [ClinicalTrials.gov：K-554查詢（本次未取得可讀結果）]","source":"","date":"","url":"https://clinicaltrials.gov/search?term=K-554&viewType=Card"},{"title":"[6] [Wegovy美國處方資訊（Revised 06/2026）]","source":"","date":"","url":"https://www.novo-pi.com/wegovy.pdf"},{"title":"[7] [Nature：Dissociable hindbrain GLP1R circuits for satiety and aversion（2024-07-10）]","source":"","date":"","url":"https://www.nature.com/articles/s41586-024-07685-6"}],"images":[{"alt":"左側腸道訊號指向腦部食慾調控；右側為實驗室和抽象候選分子，標示不同生物學與標的未公開。兩側連到增加治療選項的文件，底部標示人體價值仍待驗證。","url":"https://drugnews.com.tw/assets/articles/novo-kallyope-non-incretin-obesity-programs/FIG01_ZH_v1.png"},{"alt":"三條獨立研發列依序呈現K-554胜肽、第一項小分子和第二項小分子。日曆、文件與實驗室圖示對照每週一次設計、公司IND-ready描述、新標的及先導化合物優化；未知受體和標的以問號標示。","url":"https://drugnews.com.tw/assets/articles/novo-kallyope-non-incretin-obesity-programs/FIG02_ZH_v1.png"},{"alt":"中央K-554文件寫公司研發描述IND-ready，分別以細虛線連到監管文件、研究參與者、採樣與中性紀錄、量測及日曆四種證據領域。沒有曲線或結果數字；清楚標示公開證據待確認、待確認不等於未發生。","url":"https://drugnews.com.tw/assets/articles/novo-kallyope-non-incretin-obesity-programs/FIG03_ZH_v2.png"},{"alt":"中央中性人體輪廓連到安全性盾牌、耐受與持續使用的紀錄、效果與持續性的量測和時間，以及單用或併用的治療路徑。四個節點表示待累積的證據，沒有瘦身前後比較、曲線或成功標記。","url":"https://drugnews.com.tw/assets/articles/novo-kallyope-non-incretin-obesity-programs/FIG04_ZH_v1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/novo-kallyope-non-incretin-obesity-programs/FIG01_ZH_v1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-30）。已有瘦瘦針，諾和諾德為何還要布局另一條減重路？。https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-09-30-novo-kallyope-non-incretin-obesity-programs-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}